Imaging hypoxia in tumours with advanced MRI

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 3, 2013, Pages 257-270

  Price, J M ^a   Robinson, S P ^a   Koh, D M ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Diagnostic imaging; Magnetic resonance imaging

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; DEOXYHEMOGLOBIN; GADOPENAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PIMONIDAZOLE; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BLOOD FLOW; BLOOD OXYGEN TENSION; BOLD SIGNAL; BREAST CANCER; CANCER RADIOTHERAPY; CAPILLARY PERMEABILITY; ELECTRON SPIN RESONANCE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXEMIA; HYPOXIA; MULTIPLE CYCLE TREATMENT; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN DIFFUSION; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TISSUE METABOLISM; TISSUE OXYGENATION;

ANIMALS; CELL HYPOXIA; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MULTIMODAL IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; TUMOR MICROENVIRONMENT;

EID: 84888782660     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Kim E, Cebulla J, Douglas Ward B, Rhie K, Zhang J, Pathak AP. Assessing breast cancer angiogenesis in vivo: Which susceptibility contrast MRI biomarkers are relevant? Magn Reson Med 2012 [Epub ahead of print].
2. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nature reviews Cancer 2002;2:38-47. (Pubitemid 37328806)
3. Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC Jr et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Research 2009;69:4502-9.
4. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Research 2012;72:5285-95.
5. Bayer C, Shi K, Astner ST, Maftei C-A, Vaupel P. Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 2011;80:965-8.
6. Magat J, Jordan BF, Cron GO, Gallez B. Noninvasive mapping of spontaneous fluctuations in tumor oxygenation using 19F MRI. Medical Physics 2010;37:5434-41.
7. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S et al. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 2003;9:5101-12. (Pubitemid 37413558)
8. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 2002;8:2323-35. (Pubitemid 34753607)
9. Ahn KH, Scott G, Stang P, Conolly S, Hristov D. Multiparametric imaging of tumor oxygenation, redox status, and anatomical structure using Overhauser-enhanced MRI-prepolarized MRI system. Magn Reson Med 2011;65:1416-22.
10. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, Lei H, Meyerand ME, Grinberg OY et al. Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. JMRI 2002;16:511-21. (Pubitemid 35257757)
11. Pacheco-Torres J, Lopez-Larrubia P, Ballesteros P, Cerdan S. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed 2011;24:1-16.
12. Robinson SP, Griffiths JR. Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philosophical transactions of the Royal Society of London Series B, Biological sciences 2004;359:987-96. (Pubitemid 38784084)
13. Zahra Ma, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007;8:63-74. (Pubitemid 44943092)
14. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA et al. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 2012;22:1451-64.
15. O'Connor JPB, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-95. (Pubitemid 46160619)
16. Ellingsen C, Egeland TAM, Gulliksrud K, Gaustad J-V, Mathiesen B, Rofstad EK. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009;73:838-45.
17. Øvrebø KM, Gulliksrud K, Mathiesen B, Rofstad EK. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2011;81:255-61.
18. Egeland TAM, Gulliksrud K, Gaustad J-V, Mathiesen B, Rofstad EK. Dynamic contrast-enhanced-MRI of tumor hypoxia. Magn Reson Imaging 2012;67:519-30.
19. Gulliksrud K, Hompland T, Galappathi K, Rofstad EK. Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 2011;101:217-22.
20. Gulliksrud K, Øvrebø KM, Mathiesen B, Rofstad EK. Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 2011;98:360-4.
21. Vestvik IK, Egeland TA, Gaustad JV, Mathiesen B, Rofstad EK. Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast-enhanced MRI. JMRI 2007;26:1033-42. (Pubitemid 47548165)
22. Stoyanova R, Huang K, Sandler K, Cho H, Carlin S, Zanzonico PB et al. Mapping tumor hypoxia in vivo using pattern recognition of dynamic contrast-enhanced MRI data. Transl Oncol 2012;5:437-47.
23. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009;11:247-59.
24. Cooper RA, Carrington BM, Loncaster JA, Todd SM, Davidson SE, Logue JP et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53-9.
25. Newbold K, Castellano I, Charles-Edwards E, Mears D, Sohaib A, Leach M et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:29-37.
26. Donaldson SB, Betts G, Bonington SC, Homer JJ, Slevin NJ, Kershaw LE et al. Perfusion estimated with rapid dynamic contrastenhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. Int J Radiat Oncol Biol Phys 2011;81:1176-83.
27. Jansen JF, Schoder H, Lee NY, Wang Y, Pfister DG, Fury MG et al. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys 2010;77:1403-10.
28. Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gonen M, Bamboat Z et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011;18:2192-9.
29. Shukla-Dave A, Lee NY, Jansen JF, Thaler HT, Stambuk HE, Fury MG et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys 2012;82:1837-44.
30. Bokacheva L, Kotedia K, Reese M, Ricketts SA, Halliday J, Le CH et al. Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI. R Biomed 2013:151-63.
31. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.
32. Howe FA, Robinson SP, Mcintyre DJO, Stubbs M, Grif JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001;14:497-506. (Pubitemid 33150238)
33. Mendichovszky I, Jackson a. Imaging hypoxia in gliomas. Br J Radiol 2011;84 Spec No:S145-58.
34. Bryan RN. Science to practice: is T2* Enough to Assess Oxygenation? Radiology 2012;262:375-7.
35. Al-Hallaq HA, River JN, Zamora M, Oikawa H, Karczmar GS. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;41:151-9. (Pubitemid 28211314)
36. Zhao D, Jiang L, Hahn EW, Mason RP. Comparison of 1H blood oxygen level-dependent (BOLD) and 19F MRI to investigate tumor oxygenation. Magn Reson Med 2009;62:357-64.
37. Alonzi R, Padhani AR, Maxwell RJ, lor NJ, Stirling JJ, Wilson JI et al. Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. Br J Cancer 2009;100:644-8.
38. Ashkanian M, Borghammer P, Gjedde A, Ostergaard L, Vafaee M. Improvement of brain tissue oxygenation by inhalation of carbogen. Neuroscience 2008;156:932-8.
39. Howe FA, Robinson SP, Griffiths JR. Modification of tumour perfusion and oxygenation monitored by gradient recalled echo MRI and 31P MRS. NMR in Biomedicine 1996;9:208-16.
40. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magnetic Resonance Imaging 1999;17:1307-18. (Pubitemid 29534104)
41. McPhail LD, Robinson SP. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. Radiology 2010;254:110-8.
42. Robinson SP, Howe FA, Stubbs M, Griffiths JR. Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels. Br J Cancer 2000;82:2007-14. (Pubitemid 30326463)
43. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (p02) inside tumors? Magn Reson Med 2002;48:980-6. (Pubitemid 35398527)
44. Mcphail LD, Robinson SP. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. Radiology 2010;254:110-8.
45. Christen T, Lemasson B, Pannetier N, Farion R, Remy C, Barbier EL. Is T2 &z.aszt; enough to assess oxygenation? Quantitative blood oxygen level - Dependent analysis in brain tumor. Radiology 2012;262:495-502.
46. Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B, Gallez B. Physiological noise in murine solid tumours using T2&z.aszt;-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol 2004;49:3389-411. (Pubitemid 39161951)
47. Trotter MJ, Chaplin DJ, Olive PL. Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur J Cancer 1991;27:887-93.
48. Jordan BF, Crokart N, Baudelet C, Cron GO, Ansiaux R, Gallez B. Complex relationship between changes in oxygenation status and changes in R*2: the case of insulin and NS-398, two inhibitors of oxygen consumption. Magn Reson Med 2006;56:637-43. (Pubitemid 44338883)
49. Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD et al. Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T. NMR Biomed 2012;25:1321-30.
50. Kotas M, Schmitt P, Jakob PM, Flentje M. Monitoring of tumor oxygenation changes in head-and-neck carcinoma patients breathing a hyperoxic hypercapnic gas mixture with a noninvasive MRI technique. Strahlenther Onkol 2009;185(1):19-26.
51. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2002;53:1185-91. (Pubitemid 34787854)
52. Hoskin PJ, Carnell DM, Taylor NJ, Smith RE, Stirling JJ, Daley FM et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007;68:1065-71. (Pubitemid 47048571)
53. Jiang L, Weatherall PT, McColl RW, Tripathy D, Mason RP. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: A pilot study. JMRI 2013;37:1083-92.
54. Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D'Arcy JA, Stirling JJ et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 2011;80:721-7.
55. Matsumoto K, Bernardo M, Subramanian S, Choyke P, Mitchell JB, Krishna MC et al. MR assessment of changes of tumor in response to hyperbaric oxygen treatment. Magn Reson Med 2006;56:240-6. (Pubitemid 44162770)
56. Tadamura B, Hatabu H, Li W, Prasad PV, Edelman RR. Effect of oxygen inhalation on relaxation times in various tissues. J Magn Reson Imaging 1997;7:220-5. (Pubitemid 28365664)
57. Chen Q, Jakob PM, Griswold MA, Levin DL, Hatabu H, Edelman RR. Oxygen enhanced MR ventilation imaging of the lung. Magma 1998;7:153-61. (Pubitemid 29058343)
58. Edelman RR, Hatabu H, Tadamura E, Li W, Prasad PV. Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nature Medicine 1996;2:1236-9. (Pubitemid 26375408)
59. Jones RA, Ries M, Moonen CT, Grenier N. Imaging the changes in renal T1 induced by the inhalation of pure oxygen: a feasibility study. Magn Reson Med 2002;47:728-35. (Pubitemid 34263786)
60. Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Halliday J et al. Exploring DeltaR(2) &z.aszt; and DeltaR(1) as imaging biomarkers of tumor oxygenation. J Magn Reson Imaging 2013 [Epub ahead of print].
61. Remmele S, Sprinkart AM, Müller A, Träber F, von Lehe M, Gieseke J et al. Dynamic and simultaneous MR measurement of R(1) and R(2) &z.aszt; changes during respiratory challenges for the assessment of blood and tissue oxygenation. Magn Reson Med 2013 doi: 10.1002/mrm.24864.
62. Jordan BF, Magat J, Colliez F, Ozel E, Fruytier AC, Marchand V et al. Mapping of oxygen by imaging lipids relaxation enhancement: a potential sensitive endogenous MRI contrast to map variations in tissue oxygenation. Magn Reson Imaging 2012;000:1-13.
63. Koh DM, Padhani AR. Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology. Magn Reson Imaging Clin N Am 2010;18:565-85.
64. Tran LB, Bol A, Labar D, Jordan B, Magat J, Mignion L et al. Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol 2012;105:29-35.